Clinical trial NCT06648733: Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care
Official title: Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care (Optimierung Der Pharmakologischen Überleitung Von Palliativpatient:Innen Von stationär Nach Ambulant)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cancer
Heart Failure
COPD
Keywords: Palliative Care
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
Collaborators: name: University Hospital Munich
First posted: 2024-10-18
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The transition of palliative care patients from inpatient to outpatient care is aimed to be improved through structured pharmaceutical discharge management by a trained pharmacist. This data will be compared with retrospective cases.

Detailed description: As part of a prospective observational study with a retrospective comparison group, a pharmacist should, on request, check the discharge medication planned by the primary care physicians before discharge and discuss it with the various colleagues providing (follow-up) care. In addition, the availability in the outpatient "medicine cabinet" and the possibility of prescribing by the responsible GPs (by telephone) should be checked in advance. In addition, longitudinal focus groups with relevant stakeholders are to be conducted to collect quantitative data as well as qualitative data on the views of those providing and receiving treatment.

There will be cooperation with the Specialized Outpatient Palliative Care Service Muenster to ensure sufficient case numbers and a low rate of missing values through partial use of the standard care data from the "Information System Palliative Care" (ISPC) program they use.

Eligibility criteria: Inclusion Criteria:

All individual indications for general and specialised palliative care as part of routine clinical practice (e.g.):

* advanced, malignant tumour disease
* advanced, chronic obstructive pulmonary disease
* Patients with advanced disease and limited life expectancy (approx. 12 months) Further care in the SOPC Muenster (prospective data) Sufficient understanding of the German language to be able to understand the information and consent form

Exclusion Criteria:

Impossibility of understanding the information and declaration of consent.

Primary outcomes:
measure: (I) Drug-related problems
timeFrame: 12 months
measure: (II) Drug-related problems
timeFrame: 12 months
Secondary outcomes:
measure: Number of contacts
timeFrame: 12 months
measure: Number of readmissions / visits
timeFrame: 12 months
measure: Symptom burden
timeFrame: 12 months
measure: (I) Medication changes
timeFrame: 12 months
measure: Adoption rate
timeFrame: 12 months
measure: (I) GP contact
timeFrame: 12 months
measure: (I) SOPC contact
timeFrame: 12 months
measure: (I) Post-discharge medication changes
timeFrame: 12 months
measure: Focus groups
timeFrame: 12 months
measure: (I) Further parameters
timeFrame: 12 months
measure: (II) Medication changes
timeFrame: 12 months
measure: (II) GP contact
timeFrame: 12 months
measure: (II) SOPC contact
timeFrame: 12 months
measure: (II) Post-discharge medication changes
timeFrame: 12 months
measure: (II) Further parameters
timeFrame: 12 months
Other outcomes:
Locations:
city: Muenster
country: Germany
facility: University Hospital Muenster
state: North Rhine-Westphalia
Study officials:
affiliation: Pharmacy of the University Hospital Muenster
name: Christoph Klaas, Dr. rer. nat.
role: STUDY_CHAIR
References: